Literature DB >> 8147272

Altered leukotriene B4 levels by HL-60 cells after monocytic/macrophage differentiation.

G Hotter1, I Ramis, D Closa, J Roselló-Catafau, E Gelpí.   

Abstract

The differentiation of HL-60 human promyelocytic leukaemia cells into specific monocytic or granulocytic lineage cells depending of the inductor agent is accompanied by selective regulation of several key enzymes involved in the synthesis of eicosanoids. In this communication we have investigated the changes in arachidonic acid metabolic profiles during phorbol 12-myristate 13-acetate (PMA)-induced monocytic differentiation of HL-60 cells. Our results show that HL-60 cells have spontaneous capacity to synthesize large amounts of LTB4, but PMA-differentiated cells lose the ability to release LTB4. Significant differences are found between HL-60 cells and PMA-treated cells in basal conditions and under ionophore stimulation. The addition of LTB4 at the time of PMA differentiation did not have effects on cell proliferation, but nordihydroguaiaretic acid (NDGA), a potent 5-lipoxygenase inhibitor, also inhibited HL-60 cell proliferation and did not have any effect on PMA-differentiated cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8147272     DOI: 10.1007/bf01976754

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  21 in total

1.  Evidence for coordinate, selective regulation of eicosanoid synthesis in platelet-derived growth factor-stimulated 3T3 fibroblasts and in HL-60 cells induced to differentiate into macrophages or neutrophils.

Authors:  M Goerig; A J Habenicht; W Zeh; P Salbach; B Kommerell; D E Rothe; W Nastainczyk; J A Glomset
Journal:  J Biol Chem       Date:  1988-12-25       Impact factor: 5.157

2.  The appearance of phospholipase and cyclo-oxygenase activities in the human promyelocytic leukemia cell line HL60 during dimethyl sulfoxide-induced differentiation.

Authors:  R W Bonser; M I Siegel; R T McConnell; P Cuatrecasas
Journal:  Biochem Biophys Res Commun       Date:  1981-02-12       Impact factor: 3.575

3.  Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis.

Authors:  G K Reid; S Kargman; P J Vickers; J A Mancini; C Léveillé; D Ethier; D K Miller; J W Gillard; R A Dixon; J F Evans
Journal:  J Biol Chem       Date:  1990-11-15       Impact factor: 5.157

4.  Arachidonic acid metabolism by a vitamin D3-differentiated human leukemic cell line.

Authors:  W F Stenson; S L Teitelbaum; Z Bar-Shavit
Journal:  J Bone Miner Res       Date:  1988-10       Impact factor: 6.741

5.  Metabolism of platelet-activating factor in human haematopoietic cell lines. Differences between myeloid and lymphoid cells.

Authors:  M C Garcia; C Garcia; M A Gijon; S Fernandez-Gallardo; F Mollinedo; M Sanchez Crespo
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

6.  Analysis of leukotriene B4 metabolism in human promyelocytic HL-60 cells.

Authors:  S Kasimir; W Schönfeld; R A Hilger; W König
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

7.  Esterification of an endogenously synthesized lipoxygenase product into granulocyte cellular lipids.

Authors:  R W Bonser; M I Siegel; S M Chung; R T McConnell; P Cuatrecasas
Journal:  Biochemistry       Date:  1981-09-01       Impact factor: 3.162

8.  Regulation of 5-lipoxygenase and 5-lipoxygenase-activating protein expression in HL-60 cells.

Authors:  C F Bennett; M Y Chiang; B P Monia; S T Crooke
Journal:  Biochem J       Date:  1993-01-01       Impact factor: 3.857

9.  Effects of lipoxygenase and glutathione pathway inhibitors on leukemic cell line growth.

Authors:  A M Miller; M K Cullen; S M Kobb; R S Weiner
Journal:  J Lab Clin Med       Date:  1989-03

10.  Prostaglandin E2 and thromboxane B2 levels in rats subjected to pancreas transplantation.

Authors:  G Hotter; J Roselló-Catafau; O Bulbena; G Gómez; J Colomer; F Pi; A Saenz; L Fernández Cruz; E Gelpí
Journal:  Prostaglandins       Date:  1990-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.